Package Leaflet: Information for the User
Pregabalina ratiopharm 75 mg Hard Capsules EFG
Read this package leaflet carefully before you start taking this medicine because it contains important information for you.
Pregabalina belongs to a group of medications used for the treatment of epilepsy, peripheral and central neuropathic pain, and generalized anxiety disorder (GAD) in adults.
Peripheral and central neuropathic pain:Pregabalina is used for the treatment of chronic pain caused by nerve damage. Various diseases can cause peripheral neuropathic pain, such as diabetes or herpes. The pain sensation could be described as heat, burning, pulsating pain, stabbing pain, acute pain, spasms, continuous pain, tingling, numbness, and pins and needles sensation. Peripheral and central neuropathic pain could also be associated with mood changes, sleep disturbances, fatigue (tiredness), and may affect physical and social activity and overall quality of life.
Epilepsy:Pregabalina is used in the treatment of certain types of epilepsy (partial seizures with or without secondary generalization) in adults. Your doctor will prescribe pregabalina to treat epilepsy when your current treatment does not control the disease. You must take pregabalina in addition to your current treatment. Pregabalina should not be administered alone, but always used in combination with other antiepileptic treatments.
Generalized anxiety disorder:Pregabalina is used in the treatment of generalized anxiety disorder (GAD). Symptoms of GAD include excessive and prolonged anxiety and worry that are difficult to control. GAD can also produce restlessness or feeling of excitement or nervousness, feeling easily fatigued (tired), difficulty concentrating, feeling mentally blank, irritability, muscle tension, or sleep disturbances. This is different from everyday life stress and tensions.
Do not take Pregabalina ratiopharm
If you are allergic to pregabalin or any of the other ingredients of this medication (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to take Pregabalina ratiopharm.
Dependence
Some people may become dependent on pregabalin (need to continue taking the medication). They may experience withdrawal effects when they stop using pregabalin (see section 3, "How to take pregabalin" and "If you interrupt pregabalin treatment"). If you are concerned that you may become dependent on pregabalin, it is essential to consult your doctor.
If you notice any of the following signs while taking pregabalin, it could be a sign that you have become dependent:
If you notice any of these signs, talk to your doctor to analyze the best plan of care for you, including when it is appropriate to stop treatment and how to do it safely.
Children and adolescents
The safety and efficacy of pregabalin have not been established in children and adolescents (under 18 years) and therefore pregabalin should not be used in this age group.
Taking Pregabalina ratiopharm with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Pregabalin and certain medications may exert a mutual influence on each other (interactions). When pregabalin is used with certain medications that have a sedative effect (including opioids), these effects may be potentiated, and may lead to respiratory failure, coma, and death. The degree of dizziness, somnolence, and decreased concentration may increase if pregabalin is taken with other medications that contain:
Oxycodone – (used as an analgesic)
Lorazepam – (used to treat anxiety)
Alcohol
This medication can be taken with oral contraceptives.
Taking Pregabalina ratiopharm with food, drinks, and alcohol
Pregabalin capsules can be taken with or without food.
It is recommended not to consume alcohol during pregabalin treatment.
Pregnancy and breastfeeding
You should not take pregabalin during pregnancy or while breastfeeding, unless your doctor has indicated otherwise. The use of pregabalin during the first 3 months of pregnancy may cause congenital anomalies in the fetus that require medical treatment. In a study that reviewed data from women in Nordic countries who took pregabalin during the first 3 months of pregnancy, 6 out of 100 babies had such congenital anomalies. This contrasts with 4 out of 100 babies born to women not treated with pregabalin in the study. Congenital anomalies of the face (cleft palate), eyes, nervous system (including the brain), kidneys, and genitals have been reported.
A reliable contraceptive method should be used in women of childbearing age.If you are pregnant or breastfeeding, believe you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Pregabalin may cause dizziness, somnolence, and decreased concentration. You should not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know if this medication affects your ability to perform these activities.
Do not take more medication than prescribed.
Your doctor will determine the appropriate dose for you.
Pregabalina is exclusively for oral use.
Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder:
If you estimate that the action of pregabalina is too strong or too weak, inform your doctor or pharmacist.
If you are an elderly patient (over 65 years old), you should take pregabalina normally, except if you have kidney problems.
Your doctor may prescribe a different dosing regimen or dose if you have kidney problems.
Swallow the capsule whole with water.
Continue taking pregabalina until your doctor tells you to stop.
If you take more Pregabalina ratiopharm than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
As a result of taking more pregabalina than you should, you may feel drowsy, confused, agitated, or restless. Seizures and loss of consciousness (coma) have also been reported.
If you forgot to take Pregabalina ratiopharm
It is essential to take the pregabalina capsules regularly at the same hour every day. If you forget to take a dose, take it as soon as you remember, unless it is time for the next dose. In that case, continue with the next dose normally. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Pregabalina ratiopharm
Do not stop taking pregabalina suddenly. If you want to stop taking pregabalina, talk to your doctor first. He will tell you how to do it. If you are going to stop treatment, this should be done gradually over a minimum of one week.
Once the treatment with pregabalina is completed, whether short-term or long-term, you should know that you may experience certain adverse effects called withdrawal effects. These effects include insomnia, headaches, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, thoughts of self-harm or suicide, pain, sweating, and dizziness. These effects may appear more frequently or severely if you have been taking pregabalina for a longer period. If you experience withdrawal effects, consult your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Very Rare: may affect up to 1 in 10,000 people
Frequency not known: cannot be estimated from available data
Once a short or long-term treatment with pregabalin is completed, you should know that you may experience certain side effects, called withdrawal effects (see “If you stop taking pregabalin”).
If you experience swelling in the face or tongue, or if your skin becomes red and blisters or peels, seek immediate medical attention.
Certain side effects, such as drowsiness, may be more frequent since patients with spinal cord injury may be taking other medications to treat, for example, pain or spasticity (tense or rigid muscles), with side effects similar to those of pregabalin, so the intensity of these side effects may increase when taken together.
The following adverse reaction has been reported in post-marketing experience: difficulty breathing, shallow breathing.
Reporting of adverse reactions
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:
By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging or in the bottleafter CAD.The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medication at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and unused medication. By doing so, you will help protect the environment.
Composition of Pregabalina ratiopharm
The active ingredient is pregabalina. Each hard capsule contains 75 mg of pregabalina.
The other components are mannitol (E-421), talc, and pregelatinized cornstarch. The capsule contains: gelatine, titanium dioxide (E-171), yellow iron oxide (E-172), red iron oxide (E-172) and printing ink composed of: shellac lacquer, black iron oxide (E-172), propylene glycol, concentrated ammonium solution, and potassium hydroxide solution.
Aspect of the product and content of the container
Pregabalina ratiopharm 75 mg are hard, opaque, pink and cream-colored gelatin capsules with "75" engraved.
Pre-cut, single-dose blisters of PVC/Aluminum, containing 56 capsules.
Blister packs of PVC/Aluminum, containing 56 capsules.
Only some container sizes may be commercially marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Teva Pharma, S.L.U.
C/Anabel Segura, 11. Edificio Albatros B, 1st floor.
Alcobendas, 28108 – Madrid
Spain
Manufacturer
Pliva Croatia, Ltd.
Prilaz baruna Filipovica 25
10.000 Zagreb
Croatia
or
Merckle GmbH
Ludwig-Merckle Strasse 3
D-89143 Blaubeuren-Weiler
Germany
Last review date of this leaflet: January 2024
The detailed information of this medicine is available on the website of the Spanish Agency of Medicaments and Health Products (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.